Nifedipine Controlled Release Tablets
Number of views:

Nifedipine Controlled Release Tablets

This product is a pink film-coated tablet, with a reddish-brown and light yellow double-layer core after removing the coating.
Retail price
Market price
Number of views:
Product serial number

This product has passed the quality and efficacy consistency evaluation of generic drugs

【Drug Name】

Generic name: preparation product

English name: Nifedipine Controlled-release Tablets

Pinyin: Xiaobendiping Kongshipian


The main active ingredient of this product: nifedipine

Chemical name: dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate

Molecular formula: C17H18N2O6

Molecular weight: 346.34


This product is a pink film-coated tablet, with a reddish-brown and light yellow double-layer core after removing the coating.


1. High blood pressure

2. Coronary heart disease

Chronic stable angina (exertion angina)




Unless otherwise prescribed by a physician, the following dosages are recommended for adults:

1. Hypertension:

30mg at a time (1 tablet at a time), once a day

2. Coronary heart disease:

Chronic stable angina (exertion angina)

30mg at a time (1 tablet at a time), once a day

The usual initial dose for treatment is 30 mg daily.

Concomitant use with CYP 3A4 inhibitors or CYP 3A4 inducers may require dose adjustment of nifedipine or omission of nifedipine.

Course of treatment: The time of medication should be determined by the doctor.

Medication method: Usually the whole tablet is swallowed with a small amount of liquid, and the time of taking the medicine is not limited by the meal time. Grapefruit juice should be avoided.

special population

Patients with hepatic impairment

Dosing in patients with mild, moderate, or severe hepatic impairment based on Child Pugh score should be carefully monitored and dose reductions may be required. The pharmacokinetics of nifedipine have not been studied in patients with severe hepatic impairment.

[Adverse reactions], [Precautions] Please refer to the instruction manual for details


· This product is contraindicated in those who are known to be allergic to nifedipine or any ingredient in this product.

Nifedipine is contraindicated in cardiogenic shock.

Contraindicated in patients with KOCK pouch (ileostomy after proctocolectomy)

·Due to enzyme induction, when co-administered with rifampicin, nifedipine cannot achieve effective plasma levels. Therefore, it should not be used in combination with rifampicin.

Nifedipine is contraindicated within 20 weeks of pregnancy and lactating women.


Keep away from light, keep sealed below 30°C, and take it immediately after taking it out of the aluminum-plastic plate.

Keep medicines out of the reach of children.


Polyvinyl chloride/polyvinylidene chloride solid pharmaceutical composite hard sheet and aluminum foil for pharmaceutical packaging, 10 pieces/board×1 board/box; 10 pieces/board×2 boards/box; 10 pieces/board×4 boards/box .


24 months tentatively

Note that this product cannot be taken after the expiration date.

【Marketing Authorization Holder】

Company name: Hefei Huafang Pharmaceutical Technology Co., Ltd.


Company Name: Hefei Spree Pharmaceutical Co., Ltd.

We could not find any corresponding parameters, please add them to the properties table

keyword:Chemical products,Chinese medicine products


Huafang Pharmceutical Sciences



Add: Building D-5, Technology Industrial Park, 168 Xiangzhang Avenue, National High-tech Zone, Hefei City





Copyright © Huafang Pharmceutical